The Quantellect read.As of Nov 19, 2026, 14 active firms cover Dianthus Therapeutics Inc: 14 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $81.00 to $200.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $134.07 sits 60% above the current $83.92. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 13 to 14 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.02 next quarter toward $-4.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Buy
Strong Buy17%
Buy1393%
Neutral00%
Sell00%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$134.07
+59.8% upside
Average target across 14 active firms as of Nov 19, 2026 vs $83.92 current
Highest Target$200.00
Average Target$134.07
Lowest Target$81.00
Detailed analyst forecasts for DNTH
Showing 1–14 of 14 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 14 of 14 active firms rate DNTH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DNTH EPS & revenue forecast
EPS · NEXT QUARTER
$-1.02
Range $-1.12 – $-0.92 · 7 analysts · +20% YoY
Next period, 7 analysts expect Dianthus Therapeutics Inc. to earn $-1.02 a share (range $-1.12 – $-0.92), versus $-0.85 a year earlier. Full-year consensus is $-3.56, growing to $-4.34 the year after.
REVENUE · NEXT QUARTER
$460.3K
Range $0 – $1.5M · 7 analysts · -1% YoY
Revenue is expected to reach $460.3K (range $0 – $1.5M), -0.6% year-over-year. Full-year consensus is $2.6M, rising to $2.0M next year.
Top analysts covering Dianthus Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DNTH.
#1
Laura Chico
Wedbush · Rank #55
Buy
$122.00+45.4% to target
Overall win rate
46%
+ Follow
#2
Joel Beatty
Baird · Rank #71
Buy
$132.00+57.3% to target
Overall win rate
50%
+ Follow
#3
Yatin Suneja
Guggenheim · Rank #84
Buy
$200.00+138.3% to target
Overall win rate
50%
+ Follow
#4
Brian Cheng
JP Morgan · Rank #87
Buy
$135.00+60.9% to target
Overall win rate
51%
+ Follow
#5
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton DNTH
Overall win rate
35%
+ Follow
DNTH stock forecast FAQ
What is DNTH's average 12-month price target?+
The 14 active firms with a live target average $134.07 for Dianthus Therapeutics Inc. over the next 12 months, ranging from a $200.00 high to a $81.00 low, as of Nov 19, 2026.
Is DNTH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 14 active firms as of Nov 19, 2026, 14 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DNTH?+
The Street-high target is $200.00 (Guggenheim), and the Street-low is $81.00 (Jefferies). The average of all 14 active-firm targets is $134.07.
How many active Wall Street firms cover DNTH?+
14 active firms have a recognized rating on Dianthus Therapeutics Inc. as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DNTH?+
Among analysts who currently cover DNTH, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $122.00 target.
What is Dianthus Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.02 per share (range $-1.12 – $-0.92) across 7 analysts. Full-year EPS is projected at $-3.56, rising to $-4.34 the following year.
How much revenue is Dianthus Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $460.3K (range $0 – $1.5M). Full-year revenue is projected at $2.6M, growing to $2.0M next year.
Have analysts been upgrading or downgrading DNTH lately?+
As of Nov 19, 2026, 14 of 14 active firms rate DNTH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DNTH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.